Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
18 Apr 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
S-8
Registration of securities for employees
19 Mar 24
8-K
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
10 Jan 24
8-K
Departure of Directors or Certain Officers
20 Dec 23
S-8
Registration of securities for employees
20 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
15 Nov 23
8-K
Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Departure of Directors or Certain Officers
1 Nov 23
DEF 14A
Definitive proxy
5 Oct 23
8-K
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
26 Sep 23
PRE 14A
Preliminary proxy
21 Sep 23
8-K
Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development
19 Sep 23
424B3
Prospectus supplement
11 Sep 23
EFFECT
Notice of effectiveness
11 Sep 23
CORRESP
Correspondence with SEC
7 Sep 23
UPLOAD
Letter from SEC
6 Sep 23
S-3
Shelf registration
30 Aug 23
8-K
Other Events
29 Aug 23
D
$150.00 mm in equity / options, sold $149.95 mm, 42 investors
25 Aug 23
8-K
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
24 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Entry into a Material Definitive Agreement
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Aug 23
8-K
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
31 Jul 23
8-K
Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day
28 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
8-K
Departure of Directors or Certain Officers
22 Jun 23
8-K
Departure of Directors or Certain Officers
6 Jun 23
8-K
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial
5 Jun 23
8-K
Other Events
19 May 23
8-K
Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
8 May 23
DEFA14A
Additional proxy soliciting materials
8 May 23
DEF 14A
Definitive proxy
8 May 23
Latest ownership filings
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
TCG Crossover GP I, LLC
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Kamran Alam
6 Feb 24
4
Kamran Alam
4 Jan 24
4
Sukumar Nagendran
4 Jan 24
4
Sean P. Nolan
4 Jan 24
4
Kamran Alam
18 Dec 23
4
Sukumar Nagendran
18 Dec 23
4
Sean P. Nolan
18 Dec 23
4
Paul B Manning
20 Nov 23
4
Alison S Long
3 Nov 23
3
Alison S Long
3 Nov 23
SC 13G/A
FMR LLC
11 Sep 23
SC 13G
Venrock Healthcare Capital Partners III, L.P.
28 Aug 23
SC 13G
RA CAPITAL MANAGEMENT, L.P.
25 Aug 23
4
Kamran Alam
25 Aug 23
SC 13G
TCG Crossover GP I, LLC
25 Aug 23
144
Notice of proposed sale of securities
24 Aug 23
SC 13D/A
Manning Paul B
21 Aug 23
SC 13D/A
Astellas Pharma Inc.
18 Aug 23
4
Paul B Manning
16 Aug 23
4
John A Stalfort III
16 Aug 23
4
Sean P. Nolan
16 Aug 23
4
Phillip B. Donenberg
16 Aug 23
4
R.A. Session II
14 Jul 23
4
Laura Sepp-Lorenzino
26 Jun 23
4
Kathleen Reape
26 Jun 23
4
Phillip B. Donenberg
26 Jun 23
4
John A Stalfort III
26 Jun 23
3
John A Stalfort III
26 Jun 23
4
R.A. Session II
26 Jun 23
4
R.A. Session II
22 Jun 23
144/A
Notice of proposed sale of securities (amended)
20 Jun 23
144
Notice of proposed sale of securities
20 Jun 23
4
Kamran Alam
2 Jun 23
144
Notice of proposed sale of securities
1 Jun 23
144
Notice of proposed sale of securities
1 Jun 23